The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Patients with severe COVID-19 infection often present with acute severe inflammation and organ failure.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

The Pharma Data

JANUARY 10, 2021

Chief Executive Officer of MorphoSys, will present at the 39 th Annual J.P. EST. Live audio of the presentation can be accessed from the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com. The presentation as well as a replay of the webcast will also be available on MorphoSys’ website.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

The Pharma Data

DECEMBER 13, 2020

The FDA also recommended that Gamida Cell generate additional manufacturing-related data prior to requesting a pre-Biologics License Application (BLA) meeting. During the meeting, the FDA provided encouraging feedback regarding the Phase 3 study of omidubicel pertaining to the pre-specified primary and secondary endpoints. About Omidubicel.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-711 (COVID-19). AR-201 (RSV infection).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

JUNE 14, 2023

Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Licensing 40

Licensing Licensing Small Molecule Science 40

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. STOCKHOLM , Nov. About AlzeCure Pharma AB (publ).

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

Drug Channels

FEBRUARY 22, 2022

We also present a more unified outlook for specialty drugs, including specialty generics and biosimilars. If you have any questions before purchasing a license to the report, please email me. Download a free report overview for more details. The chart below illustrates the depth and breadth of the 2022 edition. Click to Enlarge].

Pharmacy 96

Pharmacy Specialty Pharmacies Biosimilars Licensing 96

Perficient: Drug Development

AUGUST 12, 2024

Additionally, AIS often incurs significantly lower licensing and maintenance costs, making it an attractive option for organizations looking to optimize their IT expenditure. Azure Integration Services offers a more cost-effective solution compared to MuleSoft, primarily due to its consumption-based pricing model.

Compliance 105

Compliance Licensing Licensing Production 105

DrugBank

NOVEMBER 7, 2023

The healthcare community can license ASHP data for use in new or existing software, databases, or websites in formats specific to organisational needs. “Partnering with ASHP allows us to address an industry gap that is hindering medical professionals' ability to do their best work,” he remarks.

Pharmacy 105

Pharmacy Community Pharmacies Pharmaceutical Companies Packaging 105

The Pharma Data

JANUARY 27, 2021

Renowned lymphoma expert Mats Jerkeman, MD, Lund University, will give a presentation on the current treatment landscape, and unmet medical need for patients with relapsed or refractory NHL. .” BioInvent will hold a key opinion leader (KOL) call today, Thursday, January 28 at 5:30 p.m. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Perficient: Drug Development

JANUARY 19, 2024

This distribution utilizes licensed API keys, streamlining the process for customers to conveniently retrieve and access these containers in their local registries or incorporate them seamlessly into their CI/CD pipelines.

Compliance 118

Compliance Marketing Licensing Licensing 118

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

JANUARY 7, 2021

(RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. Rakuten Medical’s Chairman and CEO, Hiroshi “Mickey” Mikitani, is scheduled to present virtually at approximately 4:30 a.m.

Clinical Trials 40

Clinical Trials Therapies Trials Licensing 40

Drug Hunter

APRIL 20, 2023

The development of a commercial manufacturing process involving deuterated building blocks is notable given the fact that the non-deuterated species has different pharmacology (lower selectivity due to an active metabolite), presenting a significant CMC challenge that needed to be overcome.

Small Molecule 130

Small Molecule Clinical Trials Trials Licensing 130

Advarra

APRIL 30, 2024

A cross-check ensures curriculum vitae (CVs), and medical licenses (if appropriate) are on file and current. The FDA 1572 Form, CV, financial disclosure form, and medical license should all show consistency regarding the PI’s name. Both the medical licenses and nurse licenses need to be up to date.

Licensing 52

Licensing Licensing Pharmacy FDA 52

Fierce BioTech

DECEMBER 13, 2023

7 “Make or Break” Factors for Emerging Biopharma Companies This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Licensing 52

Licensing Licensing Science Production 52

The Pharma Data

DECEMBER 13, 2020

A webcast of the conference call will be available under “News and Presentations” in the Investors & Media section of Relay Therapeutics’ website at [link]. To access the live call, please dial 1 (833) 540-1168 (domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

Fierce BioTech

JULY 12, 2023

With so many sources of data, both in-house and licensed, we know it can be hard to sort through it all and analyze what you need to answer your research questions. Real-World Data for Cardiovascular Disease Research These days, top-tier biopharma companies are using real-world data (RWD) to power their cardiovascular disease research.

Disease 52

Disease Research Licensing Licensing 52

FDA Law Blog: Biosimilars

JANUARY 11, 2024

HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico. Two Hyman, Phelps & McNamara, P.C.

Pharmaceuticals 59

Pharmaceuticals Licensing Licensing Compliance 59

Agency IQ

MARCH 25, 2024

In proposed rule, FDA offers up a (surprisingly sparse) list of drugs that present demonstrable compounding difficulties FDA yesterday released a long-awaited proposed rule on a list of drug products that present demonstrable difficulties for compounding.

FDA 40

FDA Pharmacy Drugs Production 40

The Pharma Data

JANUARY 14, 2021

Trial results were presented in a late-breaking oral presentation today by UCLA Health’s Zev Wainberg, M.D., The ASCO GI presentation slides are available on the company’s website. The presentation will feature members of the Five Prime management team and Zev A. Wainberg, M.D., About Gastric Cancer and GEJ Cancer.

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. However, there are many treatment goals that patients and their caregivers have that fall short of a cure, not only improvements but, for progressive conditions, a slowing or halting of worsening.

Therapies 119

Therapies FDA FDA Approval Treatment 119

SugarCone Biotech

JUNE 10, 2024

4-1BB enhances the response of activated T-cells to “foreign antigens”: protein fragments derived from infected, diseased or cancerous cells that are presented to T cells by antigen-presenting cells (APC). The NIMBY problem I think the “Cancer Immunity Cycle” as originally presented by Chen and Mellman ( 10.1016/j.immuni.2013.07.012

Immune Response 87

Immune Response Production Regulations Clinical Trials 87

The Pharma Data

APRIL 20, 2023

These data will be presented at the American Academy of Neurology (AAN) Annual Meeting held in Boston and virtually on April 22-27, 2023. A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified 2.

Treatment 40

Treatment Trials Disease Licensing 40

Drug Target Review

FEBRUARY 1, 2024

Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous. This can present challenges when attempting to recruit an enriched patient population for clinical trials. We were able to license a molecule from a multi-national pharmaceutical company.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

DrugBank

AUGUST 15, 2024

Intellectual Property Rights  While these partnerships offer potential, they also present challenges related to intellectual property rights and aligning institutional priorities. This highlighted the importance of defining patent scope and licensing terms in such collaborations.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

The Pharma Data

OCTOBER 15, 2020

Data was presented at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 14 through October 17, 2020 in Ottawa, Canada. N axitamab In a poster presentation, Dr. Mora presented data from the Company’s pivotal 201 multicenter study. About Y-mAbs.

Licensing 52

Licensing Licensing Production Treatment 52

Perficient: Drug Development

MARCH 5, 2024

Assigning the Right License Access to objects is determined based on the license type, such as High-Volume Customer Community, Customer Community Plus, and Partner Community. MFA mandates users to present two or more authentication factors, such as a password and a security token, to gain access to the system.

Licensing 59

Licensing Licensing International Regulations 59

The Pharma Data

NOVEMBER 9, 2021

We delivered strong functional performance, with all divisions showing strong growth instigation,” said Werner Baumann, Chairman of the Board of Management, on Tuesday when presenting the company’s third- quarter results. percent), driven by earnings in North America due to lower product returns and the after damage of license earnings.

Licensing 52

Licensing Licensing Science Production 52

FDA Law Blog: Biosimilars

APRIL 25, 2024

This Revised Draft Guidance provides considerations for manufacturers, packers or distributors (dubbed “firms”) of prescription biological reference products, biosimilar products, and interchangeable biosimilar products presenting data and information about such products in promotional materials in a truthful and non-misleading way.

Biosimilars 59

Biosimilars Production FDA Licensing 59

Drug Target Review

APRIL 9, 2024

Our approach to investigate the toxicity driven by nucleolar stress was to induce it with certain arginine-rich peptides, present in patients of ALS, which were known to accumulate at nucleoli and cause this type of stress. These compounds were later licensed to the pharmaceutical industry for clinical development.

RNA 64

RNA Cell Biology Clinical Development DNA 64

The Pharma Data

MARCH 8, 2021

These preliminary findings were presented today during Science Spotlights TM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021). Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. About Ridgeback Biotherapeutics.

Trials 69

Trials Virus RNA Research Laboratories 69

Perficient: Drug Development

OCTOBER 27, 2023

SAP Commerce Cloud hosting SmartEdit as CMS (existing components, CMS license, …) Perficient’s SAP Commerce Accelerator When we start a project there are various factors we must consider. Opt for SAP Composable Storefront if you value the reliability and support provided by a solution from SAP.

Compliance 105

Compliance Marketing Licensing Licensing 105

Drug Target Review

FEBRUARY 28, 2024

2,3 However, unlike αβ T cells, which are activated by the presentation of antigens to their TCRs, γδ T cells do not require antigen presentation to become activated. Normality sensing licenses local T cells for innate-like tissue surveillance. Kabelitz D, Serrano R, Kouakanou L, et al. Cell Mol Immunol 17:925-939 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105